The therapeutic potential of targeting regulated non-apoptotic cell death
Cell death is critical for the development and homeostasis of almost all multicellular
organisms. Moreover, its dysregulation leads to diverse disease states. Historically …
organisms. Moreover, its dysregulation leads to diverse disease states. Historically …
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
Poly (ADP-ribose) polymerase inhibition: past, present and future
The process of poly (ADP-ribosyl) ation and the major enzyme that catalyses this reaction,
poly (ADP-ribose) polymerase 1 (PARP1), were discovered more than 50 years ago. Since …
poly (ADP-ribose) polymerase 1 (PARP1), were discovered more than 50 years ago. Since …
PARP and PARG inhibitors in cancer treatment
D Slade - Genes & development, 2020 - genesdev.cshlp.org
Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …
genomic instability through radiotherapy and chemotherapy has been a powerful but …
State-of-the-art strategies for targeting the DNA damage response in cancer
Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA
damage response (DDR) and/or increased replication stress. These alterations promote the …
damage response (DDR) and/or increased replication stress. These alterations promote the …
Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer
Background Niraparib is an oral poly (adenosine diphosphate [ADP]–ribose) polymerase
(PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We …
(PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We …
[HTML][HTML] Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Intratumor heterogeneity is a major clinical problem because tumor cell subtypes display
variable sensitivity to therapeutics and may play different roles in progression. We previously …
variable sensitivity to therapeutics and may play different roles in progression. We previously …
The poly (ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Background Poly (ADP-ribose) polymerase (PARP) is implicated in DNA repair and
transcription regulation. Niraparib (MK4827) is an oral potent, selective PARP-1 and PARP …
transcription regulation. Niraparib (MK4827) is an oral potent, selective PARP-1 and PARP …
PARP inhibition: PARP1 and beyond
Recent findings have thrust poly (ADP-ribose) polymerases (PARPs) into the limelight as
potential chemotherapeutic targets. To provide a framework for understanding these recent …
potential chemotherapeutic targets. To provide a framework for understanding these recent …
Homologous recombination and its regulation
L Krejci, V Altmannova, M Spirek… - Nucleic acids research, 2012 - academic.oup.com
Homologous recombination (HR) is critical both for repairing DNA lesions in mitosis and for
chromosomal pairing and exchange during meiosis. However, some forms of HR can also …
chromosomal pairing and exchange during meiosis. However, some forms of HR can also …